



EXPRESS MAIL NO. EV889129816US

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dean Pettit and Claudia M. Jochheim  
Application No. : 09/800,016  
Filed : March 5, 2001  
For : USE OF EDTA IN STABILIZING GRANULOCYTE  
MACROPHAGE COLONY-STIMULATING FACTOR (As  
Amended)

Examiner : Lorraine Spector, Ph.D.  
Art Unit : 1647  
Docket No. : 140145.410  
Date : March 28, 2007

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

7<sup>TH</sup> SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached 7<sup>th</sup> Supplemental Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.


Please acknowledge receipt of this 7<sup>th</sup> Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

## 7th Supplemental Information Disclosure Statement

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



---

Qing Lin, Ph.D.


Registration No. 53,937

Enclosures:

7<sup>th</sup> Supplemental Information Disclosure Statement  
Cited References (2)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

(QXL:kw) 927747\_1.DOC



EXPRESS MAIL NO. EV889129816US

Sheet 1 of 1U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
140145.410APPLICATION NO.  
09/800,016**7<sup>th</sup> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
(Use several sheets if necessary)

APPLICANTS

Dean Pettit et al.

FILING DATE

March 5, 2001

GROUP ART UNIT

1647

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,654,403	08/05/97	Smith et al.	530	387.3	
	AB	5,792,838	08/11/98	Smith et al.	530	387.1	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	CA 2 200 651	09/21/98	CA		
	AL					
	AM					
	AN					
	AO					

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Geigert, John, et al., "Development and Shelf-Life Determination of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (LEUKINE®, GM-CSF)," <i>Formulation, Characterization, and Stability of Protein Drugs</i> , Rodney Pearlman and Y. John Wang, eds., Plenum Press, New York, 1996, 329-342.
	AQ	
	AR	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).